The FDA has approved Insmed’s brensocatib, the first treatment for non-cystic fibrosis bronchiectasis, a chronic and progressive lung disease affecting about 500,000 people in the U.S.
The drug was approved for use in adults and children 12 and older and is a once-daily oral medication that targets neutrophilic inflammation, a key driver of the disease, according to an Aug. 12 news release from the drugmaker.
The approval is based on results from phase 2 and phase 3 clinical trials, both of which showed significant reductions in disease exacerbations and improvements in lung function. In the phase 3 trial, the drug reduced the annual rate of exacerbations by over 20% compared to the placebo. The drug is now available in the U.S. for prescription use, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
